Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322955 · ClinicalTrials.gov registry record · Phase 2
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Mark Stein.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT04322955 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by Mark Stein. The registered enrollment target is 48 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04322955, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by Mark Stein.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
- PROCEDURE Cytoreductive nephrectomy
Study Locations (4)
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center - Columbus
New Jersey
- The Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322955
The ClinicalTrials.gov registry entry for NCT04322955 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Mark Stein, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04322955 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04322955 about?
NCT04322955 is a clinical study titled "CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition". The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
What is the current status of trial NCT04322955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-06-22. Estimated completion is 2028-02.
What conditions does trial NCT04322955 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer.
What interventions are being tested in trial NCT04322955?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG), Cytoreductive nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04322955?
This trial is sponsored by Mark Stein, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322955 being conducted?
This trial has 4 study locations across New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.